**Clevudine**

- **Cat. No.**: HY-13859
- **CAS No.**: 163252-36-6
- **Molecular Formula**: C₁₀H₁₃FN₂O₅
- **Molecular Weight**: 260.22
- **Target**: HBV
- **Pathway**: Anti-infection
- **Storage**:
  - Powder: -20°C 3 years, 4°C 2 years, In solvent -80°C 6 months, -20°C 1 month

**SOLVENT & SOLUBILITY**

**In Vitro**

DMSO: ≥ 50 mg/mL (192.15 mM)

*“≥” means soluble, but saturation unknown.*

<table>
<thead>
<tr>
<th>Preparing Stock Solutions</th>
<th>Solvent Concentration</th>
<th>Mass</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1 mM</td>
<td>5 mg</td>
</tr>
<tr>
<td></td>
<td>1 mM</td>
<td>3.8429 mL</td>
</tr>
<tr>
<td></td>
<td>5 mM</td>
<td>0.7686 mL</td>
</tr>
<tr>
<td></td>
<td>10 mM</td>
<td>0.3843 mL</td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

**BIOLOGICAL ACTIVITY**

**Description**

Clevudine is an antiviral drug for the treatment of hepatitis B. Target: HBVClevudine is a nucleoside analog with an unnatural beta-L configuration. Clevudine showed potent antiviral activity during therapy and induced a sustained posttreatment antiviral effect for 6 months after a 12-week treatment period, and this was associated with a sustained normalization of ALT levels [1]. Clevudine showed a potent antiviral response, and its effect was higher in HBeAg-negative patients, with rapid viral load reduction after therapy. However, long-term therapy for more than 1 year resulted in the development of considerable resistance and myopathy. Therefore, we should consider alternative antiviral agents if clevudine resistance or clevudine-induced myopathy is developed in patients on clevudine for the treatment of CHB [2].

**REFERENCES**